Company Announcements
Date
Title
5 August
First cohort successfully dosed in EBC-1013 Phase I wound healing clinical trial
30 June
QBiotics appoints Sergio Duchini as Non-executive Director
25 June
QBiotics reports 80% objective response rate in injected tumours in Stage 1 of Phase IIa clinical trial of tigilanol tiglate for Soft Tissue Sarcoma
30 May
May 2025 Shareholder Update
25 March
QBiotics appoints Jefferies and Bell Potter as Joint Lead Managers
24 March
Non-executive Director resignation
28 February
February 2025 Shareholder Update
17 February
QBiotics data presented at Society of Surgical Oncology Advanced Cancer Therapies 2025 Annual Meeting
7 February
31 December 2024 Interim Financial Report
5 February
STELFONTA® label extended in Great Britain
23 January
QBiotics strengthens medical leadership with appointment of CMO and world leading oncologist consultant